Drug intelligence / Profile preview

HRS-4006

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Small Molecules
Administration: Oral

Overview

HRS-4006 is a small molecule inhibitor targeting the KRAS protein, currently under development by Tuojie Biotech (Shanghai Tuojie Biological Technology). KRAS is a member of the RAS GTPase family and is one of the most frequently mutated oncogenes in human cancers, particularly in non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma. HRS-4006 is designed to selectively inhibit KRAS signaling to disrupt the downstream pathways that drive tumor cell proliferation and survival. The compound is part of Tuojie Biotech's oncology pipeline focusing on KRAS-driven malignancies.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on HRS-4006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-4006.

Explore the full profile